GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (FRA:9EP) » Definitions » Cyclically Adjusted PS Ratio

Enanta Pharmaceuticals (FRA:9EP) Cyclically Adjusted PS Ratio : 0.84 (As of May. 22, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2025-05-22), Enanta Pharmaceuticals's current share price is €5.05. Enanta Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €6.01. Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 0.84.

The historical rank and industry rank for Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:9EP' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.71   Med: 3.57   Max: 11
Current: 0.87

During the past years, Enanta Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 11.00. The lowest was 0.71. And the median was 3.57.

FRA:9EP's Cyclically Adjusted PS Ratio is ranked better than
84.43% of 501 companies
in the Biotechnology industry
Industry Median: 5.35 vs FRA:9EP: 0.87

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Enanta Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2025 was €0.647. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €6.01 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Enanta Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enanta Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Enanta Pharmaceuticals Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 6.42 6.49 1.56 1.41

Enanta Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.36 1.79 1.41 0.84 0.83

Competitive Comparison of Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


;
;

Enanta Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=5.05/6.01
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Enanta Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.647/134.9266*134.9266
=0.647

Current CPI (Mar. 2025) = 134.9266.

Enanta Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.536 100.684 0.718
201509 0.664 100.392 0.892
201512 2.308 99.792 3.121
201603 0.617 100.470 0.829
201606 0.655 101.688 0.869
201609 0.595 101.861 0.788
201612 0.519 101.863 0.687
201703 0.440 102.862 0.577
201706 0.350 103.349 0.457
201709 3.113 104.136 4.033
201712 1.617 104.011 2.098
201803 1.734 105.290 2.222
201806 2.332 106.317 2.960
201809 2.733 106.507 3.462
201812 2.952 105.998 3.758
201903 1.663 107.251 2.092
201906 1.860 108.070 2.322
201909 2.232 108.329 2.780
201912 2.278 108.420 2.835
202003 1.255 108.902 1.555
202006 0.827 108.767 1.026
202009 1.000 109.815 1.229
202012 1.299 109.897 1.595
202103 0.838 111.754 1.012
202106 0.888 114.631 1.045
202109 0.991 115.734 1.155
202112 1.200 117.630 1.376
202203 0.827 121.301 0.920
202206 0.890 125.017 0.961
202209 0.989 125.227 1.066
202212 1.070 125.222 1.153
202303 0.790 127.348 0.837
202306 0.828 128.729 0.868
202309 0.842 129.860 0.875
202312 0.783 129.419 0.816
202403 0.741 131.776 0.759
202406 0.788 132.554 0.802
202409 0.621 133.029 0.630
202412 0.763 133.157 0.773
202503 0.647 134.927 0.647

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Enanta Pharmaceuticals  (FRA:9EP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Enanta Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Enanta Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Enanta Pharmaceuticals Headlines

No Headlines